Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267600 | 0.87 | AURKA (0.47) | AURKAAURKBRIPK1 | |
| SCHEMBL802120 | 0.81 | KDM4E (0.42) | — | |
| SCHEMBL802732 | 0.78 | GSK3B (0.56) | AURKAAURKBIGF1R | |
| SCHEMBL802074 | 0.78 | CYP1A2 (0.50) | AURKAAURKBRIPK1NTRK1 | |
| SCHEMBL802122 | 0.76 | AURKA (0.49) | AURKAAURKBIGF1R | |
| SCHEMBL3793220 | 0.72 | AURKA (0.64) | AURKAAURKBNTRK1 | |
| SCHEMBL802841 | 0.72 | CDK2 (0.41) | — | |
| SCHEMBL802717 | 0.71 | CYP1A2 (0.50) | AURKA | |
| SCHEMBL802067 | 0.71 | AURKA (0.38) | AURKAAURKBIGF1R | |
| SCHEMBL3156916 | 0.70 | AURKA (0.59) | AURKAAURKBRIPK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256170-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, CDK3, GSK3A | AURKA 7/4885AURKB 12/4885RIPK1 191/4885 |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | AURKA 8/4885AURKB 19/4885RIPK1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.